Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IRIX Stock Forecast 2026-2027
$1.04
Current Price
$18.00M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to IRIX Price Targets
+164.4%
To High Target of $2.75
+164.4%
To Median Target of $2.75
+164.4%
To Low Target of $2.75
IRIX Price Momentum
+6.1%
1 Week Change
-22.4%
1 Month Change
+9.5%
1 Year Change
-8.8%
Year-to-Date Change
-37.0%
From 52W High of $1.65
+20.9%
From 52W Low of $0.86
📊 TOP ANALYST CALLS
Did IRIX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if IRIDEX is one of their latest high-conviction picks.
Latest IRIX Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, IRIX has a bullish consensus with a median price target of $2.75 (ranging from $2.75 to $2.75). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.04, the median forecast implies a 164.4% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IRIX Analyst Ratings
1
Buy
0
Hold
0
Sell
IRIX Price Target Range
Low
$2.75
Average
$2.75
High
$2.75
Current: $1.04
Latest IRIX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IRIX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2024 | Stifel | Thomas Stephan | Hold | Maintains | $2.00 |
| Aug 26, 2022 | Stifel | Thomas Stephan | Hold | Downgrade | $3.00 |
| May 12, 2021 | Roth Capital | Scott Henry | Buy | Maintains | $11.00 |
| Mar 3, 2021 | Roth Capital | Scott Henry | Buy | Maintains | $9.00 |
| Jan 13, 2021 | Roth Capital | Scott Henry | Buy | Maintains | $6.00 |
| May 12, 2020 | Stifel | Buy | Maintains | $4.00 | |
| Jan 4, 2019 | Stifel | Jonathan Block | Buy | Maintains | $7.00 |
| Jan 4, 2019 | Stifel Nicolaus | Buy | Maintains | $N/A | |
| Oct 26, 2018 | Stifel | Buy | Initiates | $N/A | |
| Oct 26, 2018 | Stifel Nicolaus | Buy | Initiates | $N/A | |
| Dec 21, 2016 | Roth Capital | Buy | Initiates | $N/A | |
| Jan 26, 2016 | Singular Research | Buy | Initiates | $N/A |
Iridex Corporation (IRIX) Competitors
The following stocks are similar to IRIDEX based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Iridex Corporation (IRIX) Financial Data
Iridex Corporation has a market capitalization of $18.00M with a P/E ratio of -4.0x. The company generates $52.68M in trailing twelve-month revenue with a -8.4% profit margin.
Revenue growth is +16.0% quarter-over-quarter, while maintaining an operating margin of -0.1% and return on equity of -126.4%.
Valuation Metrics
Market Cap
$18.00M
Enterprise Value
$22.50M
P/E Ratio
-4.0x
PEG Ratio
0.0x
Price/Sales
0.3x
Growth & Margins
Revenue Growth (YoY)
+16.0%
Gross Margin
+37.2%
Operating Margin
-0.1%
Net Margin
-8.4%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+33.5%
Current Ratio
1.9x
Debt/Equity
92.1x
ROE
-126.4%
ROA
-5.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Iridex Corporation (IRIX) Business Model
About Iridex Corporation
What They Do
Develops laser systems for eye disease treatment.
Business Model
Iridex Corporation generates revenue by creating and selling advanced laser systems specifically aimed at treating various eye diseases. The company's innovative technologies, such as MicroPulse, cater to the growing demand for minimally invasive procedures, allowing for safer, more effective treatments that appeal to both healthcare providers and patients.
Additional Information
Iridex is dedicated to improving patient outcomes through collaboration with ophthalmic professionals and research institutions. The company positions itself as a leader in the therapeutic laser market, responding to the increasing preference for non-incisional treatments and enhancing its offerings to meet healthcare needs.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
93
CEO
Mr. Patrick Mercer
Country
United States
IPO Year
1996
Website
www.iridex.comIridex Corporation (IRIX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Iridex's Q4 Loss Narrows Year Over Year on Retina Sales Growth
IRIX incurs narrower year-over-year loss per share in Q4 as growth in retina systems and glaucoma probes boosts revenues, though margins remain pressured by higher costs.
Apr 01, 2026
By Zacks Equity Research
Microcap Article
Latest News
Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology
2 days ago
Quick Summary
Iridex Corporation (Nasdaq: IRIX) has partnered with EyeProGPO to enhance its distribution of laser-based medical systems for glaucoma and retinal diseases in the U.S.
Why It Matters
Iridex's partnership with EyeProGPO enhances its market reach and distribution channels, potentially increasing sales and revenue in the ophthalmology sector, which can positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
IRIX reported a narrower Q4 loss per share year-over-year, driven by revenue growth in retina systems and glaucoma probes, but faced margin pressure from increased costs.
Why It Matters
IRIX's reduced loss per share and revenue growth indicate improving financial health, potentially attracting investor interest despite ongoing margin pressures from rising costs.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
IRIDEX Corporation (IRIX) held its Q4 2025 earnings call, discussing financial results and future outlook. Specific details on performance and guidance were shared during the call.
Why It Matters
IRIDEX's Q4 2025 earnings results provide insights into its financial health, growth potential, and operational efficiency, crucial for assessing investment risks and opportunities.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
The company reported strong revenue performance for Q4 and the full year 2025, supported by ongoing operational efficiencies.
Why It Matters
Robust revenue growth signals effective management and operational efficiency, indicating potential for sustained profitability and positive future performance, which can boost investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Iridex Corporation (Nasdaq: IRIX) will release its Q4 and full year 2025 financial results and a business update on March 26, 2026, after market close.
Why It Matters
Iridex's upcoming financial results and business update could significantly impact stock performance, revealing insights into growth, profitability, and future strategies in the medical device sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Iridex Announces Plans to Relocate Headquarters
2 months ago
Quick Summary
Iridex Corporation (Nasdaq: IRIX) plans to relocate its headquarters from Mountain View to San Jose, California, enhancing its operations in the medical laser systems sector.
Why It Matters
Iridex's headquarters relocation may signal strategic growth and operational efficiency, impacting its market position and investor confidence in future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About IRIX Stock
What is Iridex Corporation's (IRIX) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Iridex Corporation (IRIX) has a median price target of $2.75. The highest price target is $2.75 and the lowest is $2.75.
Is IRIX stock a good investment in 2026?
According to current analyst ratings, IRIX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IRIX stock?
Wall Street analysts predict IRIX stock could reach $2.75 in the next 12 months. This represents a 164.4% increase from the current price of $1.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Iridex Corporation's business model?
Iridex Corporation generates revenue by creating and selling advanced laser systems specifically aimed at treating various eye diseases. The company's innovative technologies, such as MicroPulse, cater to the growing demand for minimally invasive procedures, allowing for safer, more effective treatments that appeal to both healthcare providers and patients.
What is the highest forecasted price for IRIX Iridex Corporation?
The highest price target for IRIX is $2.75 from at , which represents a 164.4% increase from the current price of $1.04.
What is the lowest forecasted price for IRIX Iridex Corporation?
The lowest price target for IRIX is $2.75 from at , which represents a 164.4% increase from the current price of $1.04.
What is the overall IRIX consensus from analysts for Iridex Corporation?
The overall analyst consensus for IRIX is bullish. Out of 4 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $2.75.
How accurate are IRIX stock price projections?
Stock price projections, including those for Iridex Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 10, 2026 9:31 AM UTC